News

Candel Therapeutics Expands Research Advisory Board with Dr. Jaffee

Candel Therapeutics Expands Research Advisory Board with Dr. Jaffee

Candel Therapeutics Expands Research Advisory Board with Dr. Jaffee

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ: CADL), a biopharmaceutical company at the forefront of developing innovative immunotherapies to combat cancer, recently welcomed Elizabeth M. Jaffee, M.D., to its prestigious Research Advisory Board (RAB). This strategic move aims to bolster the Company’s focus on treating borderline resectable pancreatic cancer.

Dr. Elizabeth M. Jaffee: A Leader in Cancer Research

As an esteemed figure in the field of cancer immunology, Dr. Jaffee currently holds significant positions at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, where she directs the Gastrointestinal Cancers Program and serves as the Deputy Director. Her trailblazing work on immunotherapies specifically targeting pancreatic cancer has positioned her as a leading expert, with ongoing research dedicated to clinical trials that analyze how biomarkers can inform treatment strategies.

Contributions to Cancer Research Organizations

Dr. Jaffee's leadership extends beyond her clinical responsibilities. She previously presided over the American Association for Cancer Research and has actively participated in major initiatives like the Biden Moonshot Blue Ribbon Panel. Additionally, she plays a vital role as Chief Medical Advisor to the Lustgarten Foundation for Pancreatic Cancer Research, contributing her insights to ground-breaking advancements in the field.

Enhancing Candel’s Mission

Paul Peter Tak, M.D., Ph.D., FMedSci, the President and CEO of Candel, expressed enthusiasm about Dr. Jaffee's inclusion in the RAB, stating that her expertise aligns seamlessly with Candel’s mission. The Company recently reported promising survival data from its CAN-2409 clinical program, which targets borderline resectable pancreatic cancer. Dr. Jaffee's extensive knowledge is expected to substantially influence the design and implementation of late-stage clinical trials aimed at optimizing treatment outcomes.

Innovative Cancer Treatments at Candel

Candel Therapeutics is dedicated to developing off-the-shelf multimodal biological therapies designed to elicit a personalized immune response against tumors. With two clinical-stage immunotherapy platforms leveraging genetically modified adenovirus and Herpes simplex virus (HSV), Candel is paving the way for innovative treatments. The lead product candidate, CAN-2409, has shown statistically significant outcomes in recent trials. In a randomized phase 2a trial focusing on borderline resectable pancreatic cancer, patients receiving CAN-2409 combined with standard care exhibited significantly improved median overall survival rates compared to those receiving standard care alone.

Advancements in Cancer Immunotherapy

The Company is also developing CAN-3110, the lead candidate from its HSV platform, which is currently undergoing a phase 1b clinical trial for recurrent high-grade glioma. Candel’s enLIGHTEN™ Discovery Platform systematically explores new viral immunotherapies, employing cutting-edge human biological insights and analytics to create significant advances in treating solid tumors.

Looking Ahead

As Candel continues to forge its path in clinical development, the insights from Dr. Jaffee and the dedicated RAB promise to amplify the Company’s efforts to deliver breakthrough immunotherapy solutions to patients battling cancer.

Frequently Asked Questions

What is the role of Elizabeth Jaffee at Candel Therapeutics?

Dr. Elizabeth Jaffee has joined Candel's Research Advisory Board to provide expertise in cancer immunology and pancreatic cancer research.

What is CAN-2409?

CAN-2409 is Candel's lead product candidate designed to treat borderline resectable pancreatic cancer, showing promise in recent clinical trials.

What therapeutic approaches does Candel Therapeutics focus on?

Candel focuses on developing multimodal biological immunotherapies that elicit a systemic anti-tumor immune response to treat various cancers.

How has Dr. Jaffee contributed to cancer research?

Dr. Jaffee has made significant contributions through her roles in leading cancer organizations and her pioneering research on immunotherapy for pancreatic cancer.

Where can I learn more about Candel Therapeutics?

For more information about Candel Therapeutics, you can visit their official website at www.candeltx.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 214

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 292

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 160

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 81

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 25

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 106

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
York Space Systems Class Action: Deadline Approaches

Updated Category News Views 135

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 116

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Hims & Hers Faces Securities Lawsuit Amid Stock Dive

Updated Category News Views 191

Hims & Hers Takes a Hit Right out of the gate, we're seeing Hims & Hers Health, Inc. (NYSE:HIMS) embroiled in a securities class action, thanks to some good old-fashioned alleged corporate shenanigans. It's one of those times where you'd cock an eyebrow and say, "What in the world were they thinking?" The FTC has slapped them with accusations of misleading privacy claims...

Continue Reading
Honeywell Aerospace Faces Class Action: Deadline Looms

Updated Category News Views 93

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Continue Reading

Top 5 Most Recently Viewed Articles

Beijing's EV Export Rules Impact NIO and Li Auto Stocks

Updated Category News Views 298

Beijing Implements Stricter EV Export Regulations Affecting Stocks Recently, Chinese electric vehicle (EV) stocks NIO (NYSE: NIO) and Li Auto (NASDAQ: LI) have experienced a notable decline following announcements regarding new regulations by Beijing aimed at tightening the export of EVs. New Export Permit Requirements Effective from January 1, the Ministry of Commerce in...

Continue Reading
OceanaGold Set to Announce Q2 2025 Financial Results Soon

Updated Category News Views 122

Upcoming Financial Results from OceanaGold OceanaGold Corporation (TSX: OGC, OTCQX: OCAND) is gearing up to release its operational and financial results for the second quarter of 2025. This detailed announcement will take place after the market close, and it’s expected to shed light on the company's recent performance and highlight future prospects. Conference Call...

Continue Reading
India's July Industrial Growth Surpasses Expectations by 0.1%

Updated Category News Views 121

India's Industrial Output Shows Promising Growth in July Recent government data reveals that India's industrial output rose by a noteworthy 4.8% year-on-year in July. This figure has drawn attention since it slightly exceeds economists' forecast of 4.7% for the same month. These growing numbers reflect a resilient manufacturing sector that is steadily recovering....

Continue Reading
VideoAmp Extends Partnership with Paramount Global for Measurement

Updated Category News Views 180

VideoAmp and Paramount Global Strengthen Their Collaboration VideoAmp, a pioneering media measurement company, has recently announced the continuation of its long-term collaboration with Paramount Global. This partnership reflects a commitment to evolving the advertising landscape with precise audience insights. Comprehensive Audience Measurement This renewal provides...

Continue Reading
Empire State Realty Trust Delivers Strong Q3 Performance and Guidance

Updated Category News Views 53

Empire State Realty Trust Shows Remarkable Q3 Financial Results Empire State Realty Trust (NYSE: ESRT) demonstrated impressive financial outcomes in its most recent earnings call for the third quarter of 2024, surpassing analyst expectations significantly. The real estate investment trust revealed a Funds From Operations (FFO) totaling $69 million, translating to $0.26...

Continue Reading